NCT06962839: An ongoing trial by Boehringer Ingelheim
This trial is ongoing. It must report results 2 years, 8 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06962839 |
|---|---|
| Title | A Randomised, Double-masked, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Oral BI 1815368 in Participants With Centre-involved Diabetic Macular Edema for 48 Weeks of Treatment (THULITE) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 5, 2025 |
| Completion date | Sept. 1, 2027 |
| Required reporting date | Aug. 31, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |